Clinical Updates
Perioperative Durvalumab Plus FLOT Improves Event-Free Survival in Resectable Gastric and Gastroesophageal Junction Cancer: Results from the MATTERHORN Trial
By MedXY|Sep 30, 2025
Adding perioperative durvalumab to standard FLOT chemotherapy significantly improves event-free survival and pathological response in resectable gastric and gastroesophageal junction adenocarcinoma without increasing severe adverse events.
